Vivanta 49 mg+51 mg (Tablet)
Unit Price: ৳ 80.00 (1 x 10: ৳ 800.00)
Strip Price: ৳ 800.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sacubitril valsartan |
| Company | Beximco pharmaceuticals ltd |
| Also available as |
Indications
- Reduction of cardiovascular death risk
- Hospitalization risk reduction for heart failure
- Treatment of symptomatic heart failure in pediatric patients
- Administered in conjunction with other heart failure therapies
Pharmacology
- Contains neprilysin inhibitor sacubitril
- Contains angiotensin receptor blocker valsartan
- Inhibits neprilysin via LBQ657
- Blocks angiotensin II type-1 receptor via valsartan
- Increases levels of peptides degraded by neprilysin
- Simultaneously inhibits effects of angiotensin II by valsartan
- Inhibits angiotensin II-dependent aldosterone release
Dosage & Administration
- Recommended starting dose for adults
- Recommended starting dose for pediatric patients
- Dose titration guidelines based on patient weight
Interaction
- Dual blockade of the Renin-Angiotensin-Aldosterone System
- Potassium-sparing Diuretics
- NSAIDs
- Lithium
Contraindications
- Hypersensitivity to any component
- History of angioedema related to previous ACE inhibitor or ARB therapy
- Concomitant use of ACE inhibitors
- Concomitant use of aliskiren in patients with diabetes
Side Effects
- Angioedema
- Hypotension
- Impaired renal function
- Hyperkalemia
- Cough
- Dizziness
Pregnancy & Lactation
- Safety and effectiveness in pediatric patients
- Safety in elderly patients
- No dose adjustment required in mild hepatic impairment
- Not recommended in severe hepatic impairment
- No dose adjustment required in mild to moderate renal impairment
- Recommended starting dose in severe renal impairment
Precautions & Warnings
- May cause angioedema
- Lowers blood pressure
- May cause symptomatic hypotension
- Monitor serum creatinine
- Monitor serum potassium
- Treat appropriately in patients with risk factors for hyperkalemia
Use in Special Populations
- Safety and effectiveness in pediatric patients
- No relevant pharmacokinetic differences in elderly patients
- Starting dose recommendations for renal impairment
- Starting dose recommendations for hepatic impairment
Overdose Effects
- Hypotension likely in overdosage
- Symptomatic treatment recommended
- Unlikely to be removed by hemodialysis due to high protein binding
Storage Conditions
- Store below 30°C
- Protect from moisture
- Keep out of reach of children